Simon H. Stertzer Acquires 22,753 Shares of BioCardia, Inc. (NASDAQ:BCDA) Stock

BioCardia, Inc. (NASDAQ:BCDA) Director Simon H. Stertzer bought 22,753 shares of BioCardia stock in a transaction that occurred on Monday, March 3rd. The stock was purchased at an average cost of $2.30 per share, for a total transaction of $52,331.90. Following the purchase, the director now owns 40,602 shares of the company’s stock, valued at $93,384.60. The trade was a 127.47 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

BioCardia Stock Performance

BCDA stock opened at $2.62 on Friday. The firm has a market cap of $12.01 million, a P/E ratio of -0.63 and a beta of 1.28. The firm’s fifty day moving average is $2.34 and its 200 day moving average is $2.44. BioCardia, Inc. has a 52 week low of $1.63 and a 52 week high of $6.90.

Institutional Trading of BioCardia

An institutional investor recently bought a new position in BioCardia stock. CM Management LLC bought a new stake in shares of BioCardia, Inc. (NASDAQ:BCDA) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 25,000 shares of the company’s stock, valued at approximately $54,000. CM Management LLC owned 0.55% of BioCardia at the end of the most recent reporting period. Hedge funds and other institutional investors own 20.57% of the company’s stock.

Analyst Ratings Changes

BCDA has been the subject of a number of research reports. Alliance Global Partners upgraded BioCardia from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 30th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of BioCardia in a research note on Wednesday, December 18th.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.